{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sulfonylureas+%28SU%29",
    "query": {
      "intervention": "Sulfonylureas (SU)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sulfonylureas+%28SU%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T17:09:52.747Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05220917",
      "title": "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Events",
        "Type2 Diabetes",
        "Renal Disease"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "DPP-4 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1RA",
          "type": "DRUG"
        },
        {
          "name": "2nd generation SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 781430,
      "start_date": "2021-08-01",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220917"
    },
    {
      "nct_id": "NCT05933174",
      "title": "Promoting Alternatives to Sulfonylureas to Improve Patient Safety in Type 2 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type2diabetes"
      ],
      "interventions": [
        {
          "name": "Prompt-sheet",
          "type": "OTHER"
        },
        {
          "name": "Usual education",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2023-10-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05933174"
    },
    {
      "nct_id": "NCT00968812",
      "title": "CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Glimepiride",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin (JNJ-28431754)",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 1452,
      "start_date": "2009-09",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 43,
      "location_summary": "Calera, Alabama • Gilbert, Arizona • Mesa, Arizona + 40 more",
      "locations": [
        {
          "city": "Calera",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00968812"
    },
    {
      "nct_id": "NCT05161429",
      "title": "BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "DPP4",
          "type": "DRUG"
        },
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Basal Insulin",
          "type": "DRUG"
        },
        {
          "name": "SLGT2",
          "type": "DRUG"
        },
        {
          "name": "SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 550000,
      "start_date": "2021-07-01",
      "completion_date": "2024-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 5,
      "location_summary": "Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Beachwood",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05161429"
    },
    {
      "nct_id": "NCT03770728",
      "title": "Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Efpeglenatide SAR439977",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Metformin alone or in combination with SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 312,
      "start_date": "2019-08-01",
      "completion_date": "2020-12-27",
      "has_results": true,
      "last_update_posted_date": "2021-12-02",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03770728"
    },
    {
      "nct_id": "NCT01691989",
      "title": "A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "aleglitazar",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 197,
      "start_date": "2012-12",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 15,
      "location_summary": "Chino, California • Los Angeles, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01691989"
    },
    {
      "nct_id": "NCT00789191",
      "title": "Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin detemir",
          "type": "DRUG"
        },
        {
          "name": "sitagliptin",
          "type": "DRUG"
        },
        {
          "name": "metformin",
          "type": "DRUG"
        },
        {
          "name": "sulphonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 222,
      "start_date": "2008-11",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-14",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 10,
      "location_summary": "Vestavia Hills, Alabama • Orange, California • Santa Monica, California + 7 more",
      "locations": [
        {
          "city": "Vestavia Hills",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Dunwoody",
          "state": "Georgia"
        },
        {
          "city": "West Seneca",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00789191"
    },
    {
      "nct_id": "NCT05214573",
      "title": "Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Type 2 Diabetes",
        "Cardiac Disease"
      ],
      "interventions": [
        {
          "name": "Glucagon like peptide 1 receptor agonist",
          "type": "DRUG"
        },
        {
          "name": "Sodium-glucose cotransporter 2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Dipeptidyl Peptidase 4 Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 386301,
      "start_date": "2021-12-01",
      "completion_date": "2025-07-22",
      "has_results": true,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05214573"
    },
    {
      "nct_id": "NCT01421459",
      "title": "A Study in Adults With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "LY2963016",
          "type": "DRUG"
        },
        {
          "name": "Lantus",
          "type": "DRUG"
        },
        {
          "name": "OAMs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 759,
      "start_date": "2011-09",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2014-12-18",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 28,
      "location_summary": "Montgomery, Alabama • Brooksville, Florida • Fort Lauderdale, Florida + 25 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Oviedo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421459"
    },
    {
      "nct_id": "NCT05751525",
      "title": "Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neurodevelopmental Disorders",
        "Intellectual Disability",
        "Development Delay",
        "ADHD",
        "Autism Spectrum Disorder",
        "Epilepsy"
      ],
      "interventions": [
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Royal Devon and Exeter NHS Foundation Trust",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "2 Years to 50 Years"
      },
      "enrollment_count": 21,
      "start_date": "2016-07-01",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-10-05T17:09:52.747Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05751525"
    }
  ]
}